All Data
A partner for the pharma and biotech industries to improve patient outcomes & quality of life
Lead Product(s): Psilocybine
Therapeutic Area: Psychiatry/Psychology Product Name: TRP-8802
Highest Development Status: Undisclosed Product Type: Small molecule
Partner/Sponsor/Collaborator: Tryp Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership August 13, 2020
Details:
AMRI will provide research, development and cGMP manufacturing of a proprietary psilocybin active pharmaceutical ingredient to support the clinical development of TRP-8802, TRP-8803 and TRP-8804 programs.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Undisclosed
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Undisclosed
Partner/Sponsor/Collaborator: US Army
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 18, 2021
Details:
PPD will work with U.S. Army Medical Materiel Development Activity’s Warfighter Brain Health Project Management Office to test the efficacy and safety of at least two pharmacotherapeutic drugs for the treatment of PTSD in U.S. military active duty personnel and veterans.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Tezampanel
Therapeutic Area: Psychiatry/Psychology Product Name: LY-293,558
Highest Development Status: Undisclosed Product Type: Small molecule
Partner/Sponsor/Collaborator: National Institute on Drug Abuse
Deal Size: $12.3 million Upfront Cash: Undisclosed
Deal Type: Funding September 17, 2020
Details:
The grant supports development of the company’s proprietary molecule, tezampanel, as a treatment for opioid withdrawal syndrome. Tezampanel has demonstrated positive results in a variety of preclinical models of seizure disorder in clinical studies.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Pterostilbene,Epigallocatechin Gallate,Sulforaphane
Therapeutic Area: Psychiatry/Psychology Product Name: QuadraMune
Highest Development Status: Undisclosed Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 28, 2020
Details:
QuadraMune™ is a nutraceutical developed by the Company which is currently in a clinical trial for prevention of COVID-19[1]. Minocycline is an antibiotic that is approved by the FDA.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Cytisinicline Analogs
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 31, 2020
Details:
The United States Patent and Trademark Office has granted Achieve a patent on novel analogs of cytisinicline, a process for their preparation, and their use in the prevention or treatment of CNS and addictive disorders.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): KUR-101
Therapeutic Area: Psychiatry/Psychology Product Name: KUR-101
Highest Development Status: Undisclosed Product Type: Small molecule
Partner/Sponsor/Collaborator: ATAI Life Sciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition July 09, 2020
Details:
Kures' flagship product, KUR-101, is a derivative of mitragynine, the major active alkaloid of the kratom plant. KUR-101 will join ATAI's pipeline of ground-breaking mental health interventions such as arketamine and psilocybin.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Duloxetine Hydrochloride
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 08, 2020
Details:
Duloxetine hydrochloride is a serotonin and norepinephrine reuptake inhibitor (SNRI) and the delayed-release capsules, for oral use, were first approved in the U.S. in 2004.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Non-opioid drug
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Undisclosed
Partner/Sponsor/Collaborator: March of Dimes
Deal Size: $1.1 million Upfront Cash: Undisclosed
Deal Type: Funding June 04, 2020
Details:
The current Innovative Challenge Grant allows Katana Pharmaceutical to develop a novel non-opioid treatment for neonatal abstinence syndrome (NAS).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): PH94B
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 28, 2020
Details:
VistaGen plans to submit its proposed protocol for a Phase 2 study of PH94B for treatment of adjustment disorder to the U.S. FDA through the FDA's new Coronavirus Treatment Acceleration Program.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
